NEW YORK ─ Agilent Technologies on Thursday announced a worldwide distribution agreement that enables it to comarket Visiopharm’s portfolio of artificial intelligence-based pathology software with Agilent’s portfolio of automated pathology staining solutions.
Santa Clara, California-based Agilent said that the agreement, which will focus first on European markets, marks its entry into digital pathology and strengthens its relationship with Visiopharm by expanding the scope of a long-term collaboration.
Financial and other terms of the agreement were not disclosed.
Prior to the announcement, Agilent and Visiopharm collaborated to validate Visiopharm’s HER2 APP with Agilent’s new HercepTest mAb pharmDx for Dako Omnis, both of which are CE marked and available for sale in Europe, Agilent said.
HercepTest mAb pharmDx includes a rabbit monoclonal antibody that provides staining for the human epidermal growth factor receptor 2, or HER2, biomarker in breast cancer tissue, and Visiopharm’s HER2 APP uses automated image analysis to reproducibly assess and score HER2 staining in brightfield digital images of breast cancer tissue sections.
Pathologists can use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest mAb pharmDx stained slides, saving valuable time for both pathologists and patients, Agilent said.
Last year, Agilent and Hoersholm, Denmark-based Visiopharm announced they would comarket Visiopharm's portfolio of AI-driven pathology solutions.